PML INC
10KSB, EX-27, 2000-08-24
PHARMACEUTICAL PREPARATIONS
Previous: PML INC, 10KSB, EX-23, 2000-08-24
Next: HENLOPEN FUND, NSAR-B, 2000-08-24



<TABLE> <S> <C>

<ARTICLE>                     5

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                    MAY-31-2000
<PERIOD-END>                         MAY-31-2000
<CASH>                                         298,382
<SECURITIES>                                         0
<RECEIVABLES>                                1,921,540
<ALLOWANCES>                                    50,482
<INVENTORY>                                  1,510,136
<CURRENT-ASSETS>                             4,025,555
<PP&E>                                       5,483,039
<DEPRECIATION>                               3,502,130
<TOTAL-ASSETS>                               6,070,410
<CURRENT-LIABILITIES>                        3,995,090
<BONDS>                                        809,354
                                0
                                    787,644
<COMMON>                                        19,970
<OTHER-SE>                                     148,365
<TOTAL-LIABILITY-AND-EQUITY>                 6,070,410
<SALES>                                     14,001,938
<TOTAL-REVENUES>                            14,001,938
<CGS>                                        8,575,632
<TOTAL-COSTS>                                8,575,632
<OTHER-EXPENSES>                             4,587,352
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             265,702
<INCOME-PRETAX>                                573,252
<INCOME-TAX>                                   181,173
<INCOME-CONTINUING>                            392,079
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   392,079
<EPS-BASIC>                                       0.17
<EPS-DILUTED>                                     0.16



</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission